Please enable Javascript
Kerri Fitzgerald
Articles by Kerri Fitzgerald
Study Shows CAR T-Cell Success in Solid Tumors
Kerri Fitzgerald
Mesothelioma
|
September 21, 2023
A phase I study presented at the American Association of Clinical Research Annual Meeting showed that chimeric antigen ...
Read More
FDA Approves Retevmo® for RET-Mutated Lung, Thyroid Cancers
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
The U.S. Food and Drug Administration approved Retevmo® (selpercatinib) for three types of RET-mutated cancer: adults ...
Read More
FDA Approves Targeted Treatment for Lung Cancer Along With Companion Diagnostic
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
The U.S. Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib) for adults with metastatic non-small cell ...
Read More
Addition of Tislelizumab to Chemotherapy in Frontline Setting Improves Survival for Lung Cancer
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
Frontline tislelizumab plus chemotherapy significantly improved progression-free survival (primary endpoint) compared ...
Read More
COPD Associated With Lung Cancer, Even in Those Who Have Never Smoked
Kerri Fitzgerald
Lung Cancer
|
September 20, 2023
A study published in Thorax found that patients with chronic obstructive pulmonary disease (COPD) who have never smoked ...
Read More
FDA Approves Imfinzi® Combination to Treat Extensive-Stage Lung Cancer
Kerri Fitzgerald
Small Cell Lung Cancer
|
September 20, 2023
The U.S. Food and Drug Administration approved Imfinzi® (durvalumab) in combination with etoposide plus either ...
Read More
FDA Approves New Firstline NSCLC Drug Combo
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
The U.S. Food and Drug Administration approved Tecentriq® (atezolizumab) in combination with Abraxane® (paclitaxel) ...
Read More
Air Pollution Associated With 9 Causes of Death, Including Cancer
Kerri Fitzgerald
Lung Cancer
|
September 20, 2023
Air pollution is linked to nine specific causes of death, including lung cancer, according to a study published in JAMA ...
Read More
U.S. Lung Cancer Survival Improving, But Still Linked to Where You Live
Kerri Fitzgerald
Lung Cancer
|
September 20, 2023
In the past decade, new lung cancer cases have decreased by 19% and five-year survival has increased by 26%, according ...
Read More
Exercise Reduces Cancer Incidence and Death in Smokers
Kerri Fitzgerald
Lung Cancer
|
September 20, 2023
Men who are current or former smokers who have higher cardiorespiratory fitness may be less likely to develop lung ...
Read More
Frontline Tagrisso® Improves Survival Compared With Other Tyrosine Kinase Inhibitors for Lung Cancer
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
First-line Tagrisso® (osimertinib) improved overall survival (OS) compared with a comparator tyrosine kinase inhibitor ...
Read More
FDA Grants Breakthrough Designation for Tepotinib for Lung Cancer With Specific Mutation
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
The U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to the oral MET inhibitor tepotinib ...
Read More
Nivolumab Significantly Improves Survival Over Docetaxel in Lung Cancer
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
Pooled data from two clinical trials showed that nivolumab (Opdivo®) resulted in a fivefold increase in five-year ...
Read More
Experimental Drug LOXO-292 Shrinks RET-Positive Tumors
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
The experimental drug LOXO-292 (now called selpercatinib) shrank tumors in nearly 70% of lung tumors with the ...
Read More
Can This HIV Drug Enhance the Effects of Chemotherapy in Lung Cancer?
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
A phase I/II study published in JAMA Oncology found that the HIV protease inhibitor Viracept® (nelfinavir mesylate) ...
Read More
Pembrolizumab Plus Vorinostat a Potential Combo for Lung Cancer
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 20, 2023
A phase I/Ib study published in Clinical Cancer Research found that treatment with the immune checkpoint inhibitor ...
Read More
FDA Approves Firstline Lung Cancer Combination
Kerri Fitzgerald
Small Cell Lung Cancer
|
September 19, 2023
The U.S. Food and Drug Administration (FDA) approved atezolizumab in combination with carboplatin and etoposide for ...
Read More
Study: Smoking Cessation Prior to Lung Cancer Surgery Is Beneficial
Kerri Fitzgerald
Lung Cancer
|
September 19, 2023
A study published in The Annals of Thoracic Surgery indicated that smoking cessation any time prior to surgery for ...
Read More
FDA Approves Atezolizumab Combination for Frontline Treatment of NSCLC
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
September 19, 2023
The U.S. Food and Drug Administration approved atezolizumab in combination with bevacizumab, carboplatin, and ...
Read More
Study: Lung Cancer Incidence Expected to Decline in Next 5 Decades
Kerri Fitzgerald
Lung Cancer
|
September 19, 2023
U.S. lung cancer mortality is projected to decrease by 79% by 2065, according to a comparative model study ...
Read More
Load More